IDH1 and chondrosarcoma: A phase I trial demonstrated the promising activity of an IDH1 inhibitor, ivosidenib, particularly in conventional chondrosarcoma, where the progression-free survival was greater than in dedifferentiated chondrosarcoma, although the study was not powered to specifically compare those groups [11].